Breaking News

Ajinomoto Bio-Pharma and Revance Therapeutics Partner

Sign manufacturing agreement for supply of DaxibotulinumtoxinA for injection.

By: Contract Pharma

Contract Pharma Staff

Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical contract development and manufacturing services, and Revance Therapeutics Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, have signed a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection.   DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review. Aji Bio-Pharma will serve as a dual supply source and provide d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters